Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this four-year study, pediatric patients with inoperable plexiform neurofibromas and type 1 neurofibromatosis treated with selumetinib frequently experienced dermatologic side effects, which required tailored management strategies and sometimes led to treatment suspension, potentially affecting tumor regrowth.

This study found that dermatologic adverse events are common in children taking MEK inhibitors, with selumetinib patients experiencing less severe reactions and a lower risk of dosage adjustments. Age was noted as a factor in the likelihood of specific skin reactions.

In this case report, a 4-year-old with neurofibromatosis type 1 experienced significant reduction in an inoperable periorbital plexiform neurofibroma and visual improvement following treatment with selumetinib.

This study observed that among children with neurofibromatosis type 1 in Russia, selumetinib treatment led to a partial reduction in plexiform neurofibroma volume in 65% of cases, with 56% showing a long-term response without surgery; common side effects included skin rash and hair issues.

This study found that trametinib and vemurafenib increased sebum production and gene expression related to lipid accumulation in hamster sebocytes, which may help explain certain side effects in patients.